Gilead Sciences (GILD) Could Be 22% Overvalued On Fresh Drug Approvals

Simply Wall St.10-19 14:30

Fresh regulatory decisions have put Gilead Sciences (GILD) back in focus for investors, following approvals for HIV therapy Bixlenvo, an expanded Trodelvy cancer indication, and Hepcludex in hepatitis...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2676506862?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/29002-card/1789028982321","is_english":true,"pubTime":"2026-10-19 14:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2676506862","market":"sg","top_or_hot":-1,"title":"Gilead Sciences (GILD) Could Be 22% Overvalued On Fresh Drug Approvals","media":"Simply Wall St.","content":"<div>\n<p>Fresh regulatory decisions have put Gilead Sciences (GILD) back in focus for investors, following approvals for HIV therapy Bixlenvo, an expanded Trodelvy cancer indication, and Hepcludex in hepatitis...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gild/gilead-sciences/news/gilead-sciences-gild-could-be-22-overvalued-on-fresh-drug-ap\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Sciences (GILD) Could Be 22% Overvalued On Fresh Drug Approvals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Sciences (GILD) Could Be 22% Overvalued On Fresh Drug Approvals\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-19 14:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gild/gilead-sciences/news/gilead-sciences-gild-could-be-22-overvalued-on-fresh-drug-ap><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Fresh regulatory decisions have put Gilead Sciences (GILD) back in focus for investors, following approvals for HIV therapy Bixlenvo, an expanded Trodelvy cancer indication, and Hepcludex in hepatitis...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gild/gilead-sciences/news/gilead-sciences-gild-could-be-22-overvalued-on-fresh-drug-ap\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TMED","symbol_name":"T. Rowe Price Health Care ETF","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gild/gilead-sciences/news/gilead-sciences-gild-could-be-22-overvalued-on-fresh-drug-ap","article_id":"2676506862","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/29002-card/1789028982321"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gild/gilead-sciences/news/gilead-sciences-gild-could-be-22-overvalued-on-fresh-drug-ap","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2676506862","pubTimestamp":1792391408,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Fresh regulatory decisions have put Gilead Sciences (GILD) back in focus for investors, following approvals for HIV therapy Bixlenvo, an expanded Trodelvy cancer indication, and Hepcludex in hepatitis delta.\nThose approvals have landed during a period of strong momentum for Gilead Sciences, with the share price gaining 19.9% over 90 days and 28.5% year to date, while long-term total shareholder return of 175.8% over five years shows the impact of compounding.\nSpot opportunities beyond Gilead...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"TMED":"T. Rowe Price Health Care ETF","LU0058720904.USD":"联博国际健康护理基金A","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4585":"ETF&股票定投概念","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BBH":"VanEck Biotech ETF","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","MEDI":"HARBOR HEALTH CARE ETF","BMED":"iShares Health Innovation Active ETF","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","BK4578":"CAR-T","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1674673691.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (USD) INC","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU1674673428.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AC\" (USD) ACC","TBXU":"Direxion Daily Biotech Top 5 Bull 2X ETF","LU0234570918.USD":"高盛全球核心股票组合Acc Close","IBB":"生物科技指数ETF-iShares Nasdaq","GILD":"吉利德科学","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","BIB":"Ultra纳斯达克生物科","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","BK4568":"美国抗疫概念","LU0859254822.USD":"T ROWE PRICE GLOBAL VALUE EQUITY \"A\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","BK4588":"碎股","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","IBBQ":"Invesco Nasdaq Biotechnology ETF","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","SG9999015978.USD":"利安颠覆性创新基金A","LU0882574055.USD":"富达全球健康医疗A ACC","BK4583":"猴痘概念","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC"},"translate_title":"吉利德科学 (GILD) 新药批准可能被高估 22%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBB":0.6,"BIB":0.6,"TMED":0.6,"MEDI":0.6,"GILD":1.5,"IBBQ":0.6,"BMED":0.6,"TBXU":0.6,"BBH":0.6},"content_text":"Fresh regulatory decisions have put Gilead Sciences (GILD) back in focus for investors, following approvals for HIV therapy Bixlenvo, an expanded Trodelvy cancer indication, and Hepcludex in hepatitis delta. Those approvals have landed during a period of strong momentum for Gilead Sciences, with the share price gaining 19.9% over 90 days and 28.5% year to date, while long-term total shareholder return of 175.8% over five years shows the impact of compounding. Spot opportunities beyond Gilead Sciences by scanning a hand picked 33 healthcare AI stocks that tap into similar healthcare breakthroughs and regulatory catalysts.\nGilead Sciences now trades close to its recent highs after a sharp run driven by fresh approvals. The next consideration is whether the current valuation already reflects that progress or still leaves room for a better entry at a later time. AdvertisementMost Popular Narrative: 21.7% Overvalued The most followed narrative on Gilead Sciences puts fair value at $128.38, compared with a last close of $156.19, so it frames the recent rally as moving ahead of that estimate. Gilead is transitioning from a “single-franchise HIV company” into a multi-platform biopharma with high-probability growth drivers in lenacapavir and Trodelvy, as well as high-upside optionality in cell therapy and immunology. Temporary earnings headwinds from acquisition-related charges and integration work are obscuring what could be a stronger medium-term earnings profile once the current investment phase normalizes. See why 19 investors see Gilead Sciences as 22% overvalued. Result: Fair Value of $128.38 (OVERVALUED) Still, this storyline for Gilead Sciences could be knocked off course if key late stage trials disappoint or if recent acquisitions create harder than expected integration drag. Find out about the key risks to this Gilead Sciences narrative. Another View: Cash Flow Signals A Different Story The popular Gilead Sciences narrative frames the stock as 21.7% above a $128.38 fair value, yet our DCF model points in a very different direction. On this view, GILD at $156.19 trades well below an estimated future cash flow value of $317.59, which raises a simple question. Which lens do you trust when the gap is this wide? For investors comparing story versus spreadsheet, the SWS DCF model acts as a reality check on where long term cash generation might justify today’s $156.19 price, or a very different one tomorrow. Look into how the SWS DCF model arrives at its fair value. GILD Discounted Cash Flow as at Oct 2026Next Steps Conflicting signals around Gilead Sciences often reflect a mix of enthusiasm and caution. Act quickly, test the assumptions against your own expectations, then weigh the 3 key rewards and 2 important warning signs Looking for more investment ideas beyond Gilead Sciences? Do not stop with Gilead Sciences. Use this momentum to broaden your watchlist and pressure test your thesis against other opportunities that might suit your approach even better.  Target resilient income by reviewing a hand picked group of dividend payers through 8 dividend fortresses. Hunt for value by screening companies that pair quality fundamentals with appealing entry points using 33 high quality undervalued stocks. Prioritize capital preservation and steadier rides by focusing on financially robust businesses with the 32 resilient stocks with low risk scores.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2676506862","isCrawlerRequest":true}